Avanos Medical shares are trading lower after the company reported preliminary Q4 and FY23 financial results and revised preliminary 2024 revenue guidance.
Portfolio Pulse from Benzinga Newsdesk
Avanos Medical's stock is trading lower following the release of their preliminary Q4 and FY23 financial results, along with a revised preliminary revenue guidance for 2024.
January 04, 2024 | 3:57 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Avanos Medical's stock price is down after the company released preliminary financial results for Q4 and FY23, and provided revised revenue guidance for 2024.
The negative market reaction is likely due to the preliminary financial results and revised revenue guidance not meeting investor expectations. This typically leads to a decrease in stock price as market sentiment turns bearish on the company's near-term financial outlook.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100